| Home | E-Submission | Sitemap | Contact Us |  
J Korean Cancer Assoc > Volume 28(1); 1996 > Article
Journal of the Korean Cancer Association 1996;28(1): 104-113.
소세포 폐암에서 CAV 및 EP 교대항암약물요법의 치료성적과 국한성병기에서 조기 방사선치료의 병용효과
이경희, 전진종, 김병훈, 이은정, 도준영, 정진흥, 이관호, 현명수, 심봉섭, 이현우, 정현철
Alternating Combination Chemotherapy of CAV with EP in Small Cell Lung Gancer and Effect of Concurrent Thoracic Radiotherapy in Limited Stage
Kyung Hee Lee, Jin Jong Jeon, Byung Hoon Kim, Eun Jeong Lee, Jun Young Do, Jin Hong Chung, Kwan Ho Lee, Myung Soo Hyun, Bong Sub Shim, Hyun Woo Lee, Hyun Cheol chung
In order to assess the efficacy of alternating schedule chemotherapy on the outcome of patients with small cell lung cancer and effect of concurrent thoracic radiotherapy in limited disease, fifty five eligible patients with SCLC were treated with chemotherapy consisting of cyclophosphamide, adriamycin and vincristine(CAV) alternating with etoposide and cisplatin(EP). Thoracic radiotherapy was administered to the patients with limited stage disease Overall response rate was 64% with 20% of complete response. The response rate was 78%(CR 39%,PR 39%)in the patients with limited stage disease, and 53%(CR 6%, PR 47%)in those with extensive stage disease. With median follow-up period of 14 months (341+), the median survivals in patients of limited stage and extended disease were 15 months and 10 month, respectively (p<0.02) and median survivals in patients with CR, PR, and SD+PD were 20, 11.3, 8.5months, respectively(p<0.01) In patients with limited stage patients with or without concurrent use of thoracic radiotherapy, the response rates were 82%(CR 42%, PR 41%) and 67%(CR 33%, PR 34%) and median survivals were 15.8 months and 11.8 months, respectively.There were no life threatening side effects. This results suggest that alternating chemotherapy with CAV and EP may be useful as a treatement strategy in small cell lung cancer and concurrent use of thoracic radiotherapy in limited stage patients improve survival, but it was not significant statistically.
Key words: Small cell lung cancer, Combination chemotherapy, Concurrent radiotherapy
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI